As a first-time investor, it can be daunting trying to figure out where to put your money. But don’t worry, we’ve got you covered. Join us as we cover different types of investments!

What are the most popular types of investments? | Get Rich Slow Club

Whilst none of us are the next Warren Buffett, we have the ability to "own a piece of America", as he often suggests. For this reason, we're sharing the 10 most most popular US stocks on Pearler. 

Check out Pearler's most popular US stocks

Think of community data as a compass: you can choose any stock you want, but our community keeps pointing in the same general direction - simple, diversified, and cheap ETFs. Let's take a look at the 10 most popular ETFs on Pearler.

These are Pearler's most popular ETFs

Immersion Corp (IMMR:US) Share Price | Pearler

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

The iShares S&P 500 ETF seeks to track the investment results of an index composed of large-capitalisation U.S. equities.

iShares S&P 500 Etf

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard Australian Shares Index ETF (ASX: VAS) seeks to track the performance of the ASX 300 index before account fees, expenses, and taxes. The index tracks the top 300 companies on the Australian Securities Exchange (ASX). These are mostly large and established Australian companies. It is a popular choice among passive individual investors who don't have the time or the expertise to actively invest in stocks.

Vanguard Australian Shares Index Etf

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.

Immunomedics Inc

Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

Immutep Ltd

Immersion Corporation is a licensing company focused on the invention, acceleration, and scaling, through licensing, of haptic technologies. The Company's primary business is focused on the mobility, gaming, and automotive markets, including entertainment, virtual and augmented reality, and wearables, as well as residential, commercial, and industrial Internet of Things. It provides technology solutions for mobile, automotive, gaming, and consumer electronics. It offers patent licenses and assistance such as reference designs, prototypes and enablement services to automotive makers and suppliers. Its licensees include ALPS Alpine, Continental, Preh, Panasonic, Mobase Electronics, Nippon Seiki, Vishay Intertechnology, Tokai Rika and Lexmark. In additional, the Company has licensed its patents to third party gaming peripheral manufacturers and distributors for use in spinning mass and force feedback devices controllers, steering wheels and joysticks, to be used with PC platforms. 

Immersion Corp

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company's other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.

Gilead Sciences Inc.

GoPro, Inc. produces cameras, and mountable and wearable accessories. The Company offers a family of cameras, including its cloud connected HERO11 Black, HERO10 Black, HERO9 Black and MAX cameras. Its HERO11 Black is a waterproof camera, featuring HyperSmooth 5.0 image stabilization. HERO10 Black camera offers 5,300 pixels (5.3K) video at 60 frames per second and HERO9 Black camera offers 5K video at 30 frames per second. Its MAX captures video in 360-degrees at 6K resolution and stitches to 5.6K. It offers a range of mounts and accessories, with a camera or sold separately. It also offers offer mobile and Web applications that provides a media workflow for archiving, editing, multi-clip story creation and sharing content on the fly. Its GoPro subscription service offers a range of benefits, including a camera protection plan and a platform that enables subscribers to easily access, edit and share content. It also offers lifestyle gear, such as bags, t-shirts and other soft goods.

GoPro, Inc.

HP Inc. is a global provider of personal computing and other access devices, imaging and printing products, and related technologies, solutions and services to individual consumers, small- and medium-sized businesses (SMBs) and large enterprises, including customers in the government, health and education sectors. Its segments include Personal Systems, Printing and Corporate Investments. The Personal Systems segment offers commercial and consumer desktop and notebook personal computers (PCs), workstations, thin clients, commercial mobility devices, retail point-of-sale (POS) systems, displays and peripherals, software, support and services. The Printing segment provides consumer and commercial printer hardware, supplies, services and solutions. The Printing segment is also focused on graphics and three-dimensional (3D) imaging solutions in the commercial and industrial markets. The Corporate Investments segment includes HP Labs and certain business incubation and investment projects.

HP Inc.

Innoviva, Inc. is a holding company. The Company owns a portfolio of royalties and other healthcare assets. Its royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) collaboration agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO ELLIPTA. RELVAR/BREO ELLIPTA is a once-daily combination medicine consisting of a LABA, vilanterol (VI) and an inhaled corticosteroid (ICS), fluticasone furoate (FF). Its TRELEGY ELLIPTA is a once-daily combination medicine consisting of an ICS, long-acting muscarinic antagonist (LAMA) and LABA. Its portfolio also includes sulbactam-durlobactam (SUL-DUR). It also provides GIAPREZA (angiotensin II) and XERAVA (eravacycline).

Innoviva, Inc.

Fulgent Genetics, Inc. is a technology-based company with a clinical diagnostic business and a therapeutic development business. The Company's clinical diagnostic business offers molecular diagnostic testing services, genetic testing, and anatomic pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its business is built on its technology platform, which includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The Company's technology platform offers a test menu. The Company also offers next-generation sequencing (NGS) services.

IMMR

Buy

👑 Overview

📈

N/A

Annual Growth

🌏

0

Pearlers Invested

Key information

🔎 Fund Overview

Price History*

Unsure how much or often to invest?

🗓️ Investing frequency calculator

💵 Investing amount calculator

⏱️ Investing duration calculator

💵

6.50 AUD*

Purchase Fee

💼

N/A

Management Fee

💸

Want to know the long term costs?

Calculate the historic long term costs to hold your investments

Technical Info

$7.17

How our community is investing

0

N/A

N/A

N/A

1044 days

IMMR investor breakdown

💵 Income of investors

👶 Age of investors

🙋 Legal gender of investors

$77.09 USD

Find Out More

$4.12 USD

Find Out More

$31.30 USD

Find Out More

$13.14 USD

Find Out More

$39.35 USD

Find Out More

$87.86 USD

Find Out More

$2.13 USD

Find Out More

Buy